The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient

Critical Care Nursing Clinics of North America

Volumn 17, Issue 3, 2005, Pages 245-250

  Yogaratnam, Dinesh ^a   Miller, Melissa A ^a   Smith, Brian S ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; HYPNOTIC SEDATIVE AGENT;

BIOAVAILABILITY; BLOOD FLOW VELOCITY; DRUG MONITORING; HALF LIFE TIME; HUMAN; INTENSIVE CARE; INTESTINE ABSORPTION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; LIVER DISEASE; LIVER FUNCTION TEST; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NURSING; NURSING ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; TISSUE DISTRIBUTION;

ANALGESICS; BIOLOGICAL AVAILABILITY; BLOOD FLOW VELOCITY; CRITICAL CARE; DRUG MONITORING; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; INTESTINAL ABSORPTION; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER FUNCTION TESTS; METABOLIC CLEARANCE RATE; NURSING ASSESSMENT; TISSUE DISTRIBUTION;

EID: 23944518423     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2005.04.007     Document Type: Review

References (32)

1. P.M. Atkins, L.C. Mion, and W. Mendelson Characteristics and outcomes of patients who self-extubate from ventilatory support: a case-control study Chest 112 1997 1317 1323
2. B. Walder, and M.R. Tramer Analgesia and sedation in critically ill patients Swiss Med Wkly 134 2004 333 346
3. B.M. Power, A.M. Forbes, and P.V. van Heerden Pharmacokinetics of drugs used in critically ill adults Clin Pharmacokinet 34 1998 25 56
4. A. al-Khafaji, and H.L. Corwin Acute renal failure and dialysis in the chronically critically ill patient Clin Chest Med 22 2001 165 174
5. C.W. Howden, G.G. Birnie, and M.J. Brodie Drug metabolism in liver disease Pharmacol Ther 40 1989 439 474
6. V. Rodighiero Effects of liver disease on pharmacokinetics: an update Clin Pharmacokinet 37 1999 399 431
7. I. Tegeder, J. Lotsch, and G. Geisslinger Pharmacokinetics of opioids in liver disease Clin Pharmacokinet 37 1999 17 40
8. J. Hasselstrom, S. Eriksson, and A. Persson The metabolism and bioavailability of morphine in patients with severe liver cirrhosis Br J Clin Pharmacol 29 1990 289 297
9. P.J. Pentikainen, L. Valisalmi, and J.J. Himberg Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects J Clin Pharmacol 29 1989 272 277
10. P.E. Marik The treatment of hypoalbuminemia in the critically ill patient Heart Lung 22 1993 166 170
11. T.B. Vree, M. Shimoda, and J.J. Driessen Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients Clin Pharmacol Ther 46 1989 537 544
12. J.P. Haberer, P. Schoeffler, and E. Couderc Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis Br J Anaesth 54 1982 1267 1270
13. C.G. Child The liver and portal hypertension 1964 WB Saunders Philadelphia
14. R.N. Pugh, I.M. Murray-Lyon, and J.L. Dawson Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
15. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
16. G. Davies, C. Kingswood, and M. Street Pharmacokinetics of opioids in renal dysfunction Clin Pharmacokinet 31 1996 410 422
17. U. Klotz Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications Clin Pharmacokinet 1 1976 204 218
18. T.B. Vree, Y.A. Hekster, and P.G. Anderson Contribution of the human kidney to the metabolic clearance of drugs Ann Pharmacother 26 1992 1421 1428
19. T.P. Gibson Renal disease and drug metabolism: an overview Am J Kidney Dis 8 1986 7 17
20. M.W. Anders Metabolism of drugs by the kidney Kidney Int 18 1980 636 647
21. R.W. Milne, R.L. Nation, and A.A. Somogyi The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients Br J Clin Pharmacol 34 1992 53 59
22. T.M. Bauer, R. Ritz, and C. Haberthur Prolonged sedation due to accumulation of conjugated metabolites of midazolam Lancet 346 1995 145 147
23. G. Morrison, S.T. Chiang, and H.H. Koepke Effect of renal impairment and hemodialysis on lorazepam kinetics Clin Pharmacol Ther 35 1984 646 652
24. R.W. Jelliffe Estimation of creatinine clearance when urine cannot be collected Lancet 1 1971 975 976
25. R.W. Jelliffe Letter: creatinine clearance: bedside estimate Ann Intern Med 79 1973 604 605
26. A.S. Levey, J.P. Bosch, and J.B. Lewis A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
27. F. Gaspari, S. Ferrari, and N. Stucchi Performance of different prediction equations for estimating renal function in kidney transplantation Am J Transplant 4 2004 1826 1835
28. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
29. D.S. Sherman, D.N. Fish, and I. Teitelbaum Assessing renal function in cirrhotic patients: problems and pitfalls Am J Kidney Dis 41 2003 269 278
30. J. Jacobi, G.L. Fraser, and D.B. Coursin Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult Crit Care Med 30 2002 119 141
31. B.D. Watson, and S.L. Kane-Gill Sedation assessment in critically ill adults: 2001-2004 update Ann Pharmacother 38 2004 1898 1906
32. A. Deogaonkar, R. Gupta, and M. Degeorgia Bispectral Index monitoring correlates with sedation scales in brain-injured patients Crit Care Med 32 2004 2403 2406